The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...
The US Food and Drug Administration has granted breakthrough therapy designation to Oculis’ neuroprotective candidate ...
Please provide your email address to receive an email when new articles are posted on . Being male or aged older than 40 years were consistently associated with poorer acute optic neuritis outcomes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback